Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Other Non-Current Liabilities (2024 - 2025)

Corvus Pharmaceuticals (CRVS) has 2 years of Other Non-Current Liabilities data on record, last reported at $3.8 million in Q1 2025.

  • For Q1 2025, Other Non-Current Liabilities changed N/A year-over-year to $3.8 million; the TTM value through Mar 2025 reached $3.8 million, changed N/A, while the annual FY2024 figure was $28.9 million, N/A changed from the prior year.
  • Other Non-Current Liabilities reached $3.8 million in Q1 2025 per CRVS's latest filing, down from $28.9 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $40.0 million in Q3 2024 and bottomed at $3.8 million in Q1 2025.